Welcome to our dedicated page for InspireMD news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD stock.
InspireMD, Inc. (NASDAQ: NSPR), located at 800 Boylston Street, Suite 16041, Boston, Massachusetts, is a pioneering medical device company. It specializes in the development and commercialization of its proprietary MicroNet stent platform technology, which addresses complex vascular and coronary diseases. The company's flagship products include the CGuard Carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS).
The CGuard EPS, which integrates MicroNet technology with a self-expandable nitinol stent, is primarily used for carotid artery applications and is a significant revenue driver for the company. InspireMD operates globally, with key markets in Italy, Germany, Russia, among others.
In a recent move, InspireMD has focused on expanding its intellectual property portfolio to support its strategic direction. October 2023 saw the Centers for Medicare and Medicaid Services (CMS) expand coverage for carotid artery stenting, including asymptomatic and standard-risk patients. This development is expected to enhance the adoption of InspireMD's products.
Additionally, in the third quarter of 2023, InspireMD reported its financial results and ongoing projects. They are currently enrolling patients in a study to investigate the safety and feasibility of using CGuard EPS for treating acute ischemic stroke patients with tandem lesions. This study is expected to enroll 15 patients across three U.S. sites.
CEO Marvin Slosman emphasized the importance of this study in addressing carotid lesions in acute stroke settings, marking a crucial step in their long-term growth strategy. The company also continues its work on the Premarket Approval Application (PMA) for the C-GUARDIANS U.S. IDE trial, anticipating key milestones in 2024 and 2025.
InspireMD's common stock is listed on the Nasdaq under the ticker symbol NSPR. For more information, visit their website at www.inspiremd.com.
InspireMD reported the successful closing of an upsized public offering, generating approximately $20.7 million in gross proceeds. The offering included 29,032,258 Units priced at $0.62 each, each consisting of one share of Common Stock and a Series G Warrant. Furthermore, an over-allotment option led to the purchase of an additional 4,354,838 Units. The offering, managed by A.G.P./Alliance Global Partners, was registered with the SEC. Funds raised will be critical for further business development in the competitive medical device sector.
InspireMD announced an upsized underwritten public offering of securities to raise $18 million, which could increase to $20.7 million if underwriters exercise their additional purchase option. The offering includes 29,032,258 Units priced at $0.62 each, comprising one share of Common Stock and one Series G Warrant. The offering is expected to close around February 8, 2021. A.G.P./Alliance Global Partners serves as the sole book-running manager. This follows the SEC's approval of the registration statement on Form S-1.
InspireMD has announced a partnership with Chinese distributors, including Shanghai Micro Medical, to market its CGuard™ Embolic Prevention System in mainland China. This agreement includes conducting registration trials for regulatory approval and grants an eight-year exclusive distribution right in China. Additionally, QIDI Asia Medical will invest $900,000 in a private placement of the company's stock. This move positions InspireMD to expand in a rapidly growing market, with stroke being a significant health issue in China.
InspireMD (NYSE American: NSPR) announced multiple presentations regarding the CGuard™ Embolic Prevention System at the Leipzig Interventional Congress from January 25-29, 2021. Key presentations include the IRONGUARD 2 study results and a live demonstration of CGuard implantation. The company emphasizes the advantages of CGuard over first-generation stents, citing its MicroNet technology as a potential new standard for carotid artery disease management. InspireMD aims to enhance global awareness and acceptance of CGuard for improved patient outcomes.
InspireMD, developer of the CGuard™ Embolic Prevention System (EPS), announced its third quarter 2020 results, marking a return to pre-COVID revenue levels with $980,000, up 4.4% from the previous year. The FDA approved its Investigational Device Exemption to initiate a pivotal study for CGuard EPS. Gross profit increased by 132.8% to $298,000, while total operating expenses rose 17.3% to $2,493,000. Despite a net loss of $2,233,000, a decrease from last year's loss, InspireMD remains optimistic about its growth strategy in endovascular carotid artery stent procedures and expanding into international markets.
TEL AVIV, Israel, Nov. 3, 2020 – InspireMD (NYSE American: NSPR) appointed Andrea Tommasoli as senior vice president of global sales and marketing. Tommasoli brings over 20 years of medical technology experience, previously serving in leadership roles at Integra Life Sciences and St. Jude Medical-Abbott. His expertise is expected to enhance InspireMD's sales strategy. The company also granted him 271,534 shares of restricted stock and options for 90,511 shares as part of his inducement package. The awards have a ten-year term and will vest over three years, contingent on continued employment.
InspireMD, Inc. (NYSE American: NSPR) announced the appointment of Andrea Tommasoli as senior vice president of global sales and marketing, effective immediately. With over 20 years of experience in medical technology, Tommasoli previously held leadership roles at Integra Life Sciences and St. Jude Medical-Abbott. He will oversee all sales and marketing efforts for InspireMD’s innovative CGuard™ Embolic Prevention System, aimed at improving stroke prevention in carotid artery disease. Additionally, Tommasoli received inducement awards including 271,534 shares of restricted stock and options to purchase 90,511 shares at an exercise price of $0.35.
InspireMD, a developer of the CGuard™ Embolic Prevention System, will report its fiscal third quarter 2020 financial results on November 9, 2020, before market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results and corporate updates. Registered participants will receive direct dial-in numbers, while others can call in using provided domestic and international numbers. The conference call will be available via live webcast and replay links. InspireMD aims to establish its MicroNet® technology as the industry standard for carotid stenting.
InspireMD (NYSE American: NSPR) announced the appointment of Dr. Gary Roubin to its Board of Directors. Dr. Roubin, an esteemed interventional cardiologist, is recognized for his work in carotid stenting and contributed to the development of coronary stents. His expertise is expected to enhance InspireMD's global expansion plans for its CGuard Embolic Prevention System, which has shown superior clinical outcomes. CEO Marvin Slosman highlighted Dr. Roubin's appointment as a vote of confidence in the company's potential and technology.
InspireMD, Inc. (NYSE American: NSPR) announced the appointment of Patrick Jamnik as Vice President of Business Development and Strategic Initiatives. Mr. Jamnik will focus on advancing the company’s goals, particularly in the U.S. market. He brings over 15 years of experience from roles at large medical technology firms. InspireMD granted Mr. Jamnik 162,920 shares of restricted stock and options for 54,307 shares as inducement awards. Both the restricted stock and options will vest in equal installments over three years, contingent on his employment status.
FAQ
What is the current stock price of InspireMD (NSPR)?
What is the market cap of InspireMD (NSPR)?
What does InspireMD, Inc. specialize in?
What are the key products of InspireMD?
Where is InspireMD headquartered?
In which markets does InspireMD operate?
What recent developments have been announced by InspireMD?
Who is the CEO of InspireMD?
What are the financial results for InspireMD in the third quarter of 2023?
What is the trading symbol for InspireMD?
What is the MicroNet technology?
How can I get more information about InspireMD?
